Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lumateperone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 18/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.98 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 15/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.82 |
| ▸ | DRD1 | P21728 | 1/20 | 0.82 |
| ▸ | DRD4 | P21917 | 1/20 | 0.82 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.82 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.82 |
| ▸ | CCR3 | P51677 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lumateperone SCHEMBL21524899 | 0.99 | HTR2A (1.00) | HTR2AHTR2CSLC6A4DRD2HTR1A | |
| Lumateperone SCHEMBL1468226 | 0.99 | HTR2A (1.00) | HTR2AHTR2CSLC6A4DRD2HTR1A | |
| Lumateperone SCHEMBL29355930 | 0.99 | HTR2A (1.00) | HTR2AHTR2CSLC6A4DRD2HTR1A | |
| Lumateperone SCHEMBL7996531 | 0.99 | HTR2A (1.00) | HTR2AHTR2CSLC6A4DRD2HTR1A | |
| Lumateperone SCHEMBL5513940 | 0.99 | HTR2A (1.00) | HTR2AHTR2CSLC6A4DRD2HTR1A | |
| Lumateperone SCHEMBL17681371 | 0.99 | HTR2A (1.00) | HTR2AHTR2CSLC6A4DRD2HTR1A | |
| Lumateperone SCHEMBL22067597 | 0.99 | HTR2A (1.00) | HTR2AHTR2CSLC6A4DRD2HTR1A | |
| SCHEMBL27288366 | 0.96 | HTR2A (0.95) | HTR2AHTR2CSLC6A4DRD2HTR1A | |
| SCHEMBL27290495 | 0.96 | HTR2A (0.95) | HTR2AHTR2CSLC6A4DRD2HTR1A | |
| SCHEMBL27288363 | 0.95 | HTR2A (0.93) | HTR2AHTR2CSLC6A4DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609891-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240327409-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11453670-B2 | Substituted heterocycle fused gamma-carbolines synthesis | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-20200102309-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2020-04-02 | — | — | US | disclosed |
| CN-110831941-A | Synthesis of substituted heterocycle fused gamma-carboline compound | 细胞内治疗公司 | 2020-02-21 | — | — | CN | disclosed |
| EP-3609891-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | Intra-Cellular Therapies, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102309-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | HTR2A 1243/4885SLC6A4 4002/4885DRD2 221/4885 |
| US-20240327409-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | HTR2A 1243/4885SLC6A4 4002/4885DRD2 221/4885 |
| US-11453670-B2 | Substituted heterocycle fused gamma-carbolines synthesis | HCCS, CYCS, CBR3 | HTR2A 1243/4885SLC6A4 4002/4885DRD2 221/4885 |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | HTR2A 1243/4885SLC6A4 4002/4885DRD2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.